<DOC>
	<DOCNO>NCT01640665</DOCNO>
	<brief_summary>The purpose study find maximum tolerate dose combination two drug . The two drug Sorafenib Capecitabine . The drug Sorafenib approve drug use treat certain cancer . The drug Capecitabine approve treat patient advance breast cancer well early stage colon cancer .</brief_summary>
	<brief_title>Pilot Study Sorafenib Bi-weekly Capecitabine Patients With Advanced Breast Gastrointestinal Tumors</brief_title>
	<detailed_description>This pilot study Sorafenib combine Capecitabine patient histologically confirm unresectable metastatic breast GI tumor . One cycle consist 4 week treatment . The dose Sorafenib 600 mg administer orally daily divide dos . Capecitabine give fix dose 2000 mg orally BID x 7 day every 14 day</detailed_description>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age â‰¥ 18 year . Life expectancy least 12 week ( 3 month ) . ECOG Performance Status 0 1 . Histologically confirm unresectable metastatic breast and/or GI tumor curative standard treatment unavailable Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 Total bilirubin &lt; 1.5 time ULN ALT AST &lt; 2.5 time ULN ( &lt; 5 x ULN patient liver involvement ) GFR &gt; 30 ml/min All acute toxic effect ( exclude alopecia neuropathy ) prior treatment resolve NCICTCAE v4.0 Grade 1 less time signing Informed Consent Form ( ICF ) . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign ICF least 30 day last dose study drug . The definition adequate contraception base judgment principal investigator designate associate . Subject must able swallow retain oral medication . Subjects must able understand willing sign write informed consent form . A sign informed consent form must appropriately obtain prior conduct trialspecific procedure . Metastatic brain meningeal tumor ( unless subject complete definitive therapy 1 month previously stable steroid ) . Uncontrolled hypertension define systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association ( NYHA ) &gt; Class II . Active coronary artery disease . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization . Subject pulmonary hemorrhage/bleeding event NCICTCAE v4.0 Grade 2 high within 4 week study enrollment ; hemorrhage/bleeding event NCICTCAE v4.0 Grade 3 high within 4 week study enrollment . Major surgery , open biopsy significant traumatic injury within 30 day first study drug . Presence active nonhealing wound , nonhealing ulcer , bone fracture . Thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) within 3 month inform consent . Anticoagulation warfarin permit . Evidence history bleed diathesis coagulopathy . Subjects use strong CYP3A4 inducer ( eg , phenytoin , carbamazepine , phenobarbital , St. John 's Wort [ Hypericum perforatum ] , dexamethasone dose great 16 mg daily , rifampin [ rifampicin ] , and/or rifabutin ) within 30 day trial enrollment . Subjects history dihydopyrimidine dehydrogenase ( DHPD ) deficiency severe unexpected reaction fluropyrimidines . Subjects previously untreated concurrent cancer distinct primary site histology except cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor . Subjects survive cancer curatively treat without evidence disease 3 year randomization allow . All relevant cancer treatment must complete least 3 year prior study entry ( i.e. , signature date inform consent form ) . History organ allograft . ( Including corneal transplant ) . Known human immunodeficiency virus ( HIV ) infection Hepatitis B C currently undergo active antiviral treatment . Any malabsorption problem . Anticancer chemotherapy immunotherapy study permit . Known suspect allergy hypersensitivity study drug , study drug class , excipients formulation give course trial . Women pregnant breastfeeding . Inability comply protocol and/or willing available followup assessment . Any condition , investigator 's opinion , make subject unsuitable trial participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>histologically</keyword>
	<keyword>unresectable</keyword>
	<keyword>metastatic</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>GI Tumors</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Capecitabine</keyword>
</DOC>